JP2001520189A5 - - Google Patents

Download PDF

Info

Publication number
JP2001520189A5
JP2001520189A5 JP2000516661A JP2000516661A JP2001520189A5 JP 2001520189 A5 JP2001520189 A5 JP 2001520189A5 JP 2000516661 A JP2000516661 A JP 2000516661A JP 2000516661 A JP2000516661 A JP 2000516661A JP 2001520189 A5 JP2001520189 A5 JP 2001520189A5
Authority
JP
Japan
Prior art keywords
hydrogen
independently
taxane
compound
taxanes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000516661A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001520189A (ja
Filing date
Publication date
Priority claimed from US08/954,678 external-priority patent/US5919816A/en
Application filed filed Critical
Publication of JP2001520189A publication Critical patent/JP2001520189A/ja
Publication of JP2001520189A5 publication Critical patent/JP2001520189A5/ja
Pending legal-status Critical Current

Links

JP2000516661A 1997-10-17 1998-10-16 抗腫瘍剤の毒性を低減するための調合物及び方法 Pending JP2001520189A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/954,678 US5919816A (en) 1994-11-14 1997-10-17 Formulations and methods of reducing toxicity of antineoplastic agents
US08/954,678 1997-10-17
PCT/US1998/021814 WO1999020264A1 (en) 1997-10-17 1998-10-16 Formulations and methods for reducing toxicity of antineoplastic agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2005294264A Division JP2006070041A (ja) 1997-10-17 2005-10-07 抗腫瘍剤の毒性を低減するための調合物及び方法

Publications (2)

Publication Number Publication Date
JP2001520189A JP2001520189A (ja) 2001-10-30
JP2001520189A5 true JP2001520189A5 (cg-RX-API-DMAC7.html) 2006-01-05

Family

ID=25495777

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2000516661A Pending JP2001520189A (ja) 1997-10-17 1998-10-16 抗腫瘍剤の毒性を低減するための調合物及び方法
JP2005294264A Pending JP2006070041A (ja) 1997-10-17 2005-10-07 抗腫瘍剤の毒性を低減するための調合物及び方法
JP2009237143A Pending JP2010043117A (ja) 1997-10-17 2009-10-14 抗腫瘍剤の毒性を低減するための調合物及び方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2005294264A Pending JP2006070041A (ja) 1997-10-17 2005-10-07 抗腫瘍剤の毒性を低減するための調合物及び方法
JP2009237143A Pending JP2010043117A (ja) 1997-10-17 2009-10-14 抗腫瘍剤の毒性を低減するための調合物及び方法

Country Status (12)

Country Link
US (11) US5919816A (cg-RX-API-DMAC7.html)
EP (1) EP1033981B1 (cg-RX-API-DMAC7.html)
JP (3) JP2001520189A (cg-RX-API-DMAC7.html)
CN (1) CN1276720A (cg-RX-API-DMAC7.html)
AT (1) ATE262329T1 (cg-RX-API-DMAC7.html)
AU (1) AU750521B2 (cg-RX-API-DMAC7.html)
CA (1) CA2304704C (cg-RX-API-DMAC7.html)
DE (1) DE69822659T2 (cg-RX-API-DMAC7.html)
DK (1) DK1033981T3 (cg-RX-API-DMAC7.html)
ES (1) ES2213922T3 (cg-RX-API-DMAC7.html)
PT (1) PT1033981E (cg-RX-API-DMAC7.html)
WO (1) WO1999020264A1 (cg-RX-API-DMAC7.html)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20020155999A1 (en) * 1998-04-30 2002-10-24 Han In Suk Method of using a porphyrin-like molecule conjugated with an anti-cancer drug for the treatment of cancer
US7314637B1 (en) 1999-06-29 2008-01-01 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US6075053A (en) * 1999-02-09 2000-06-13 Bionumerik Pharmaceuticals, Inc. Method of reducing or reversing neuropathy
US6197831B1 (en) * 1999-02-09 2001-03-06 Bionumerik Pharmaceuticals, Inc. Method of treating septic shock
US6395481B1 (en) * 1999-02-16 2002-05-28 Arch Development Corp. Methods for detection of promoter polymorphism in a UGT gene promoter
US20030036513A1 (en) * 1999-02-16 2003-02-20 Yurkow Edward J. Method for treating cancer
GB9904386D0 (en) * 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
US20050222246A1 (en) * 1999-04-14 2005-10-06 Li Chiang J Beta-lapachone is a broad spectrum anti-cancer agent
US20050192360A1 (en) * 1999-04-14 2005-09-01 Li Chiang J. Method of treatment of pancreatic cancer
CA2369303A1 (en) * 1999-04-14 2000-10-19 Arthur B. Pardee Method and composition for the treatment of cancer
EP1171117A4 (en) * 1999-04-22 2002-08-07 American Bioscience Inc LONG-TERM ADMINISTRATION OF PHARMACOLOGICALLY ACTIVE AGENTS
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
US6034126A (en) * 1999-05-24 2000-03-07 Bionumerik Pharmaceuticals, Inc. Method for treating glycol poisoning
GB9916882D0 (en) * 1999-07-19 1999-09-22 Pharmacia & Upjohn Spa Antitumor synergistic composition
US6294546B1 (en) * 1999-08-30 2001-09-25 The Broad Of Trustees Of The Leland Stanford Junior University Uses of diterpenoid triepoxides as an anti-proliferative agent
HK1049787B (en) 1999-10-01 2014-07-25 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
WO2001036048A1 (en) * 1999-11-15 2001-05-25 Parker Hughes Institute Phorboxazole derivatives for treating cancer
US6890946B2 (en) * 1999-12-23 2005-05-10 Indiana University Research And Technology Corporation Use of parthenolide to inhibit cancer
AU2000239101A1 (en) * 2000-03-22 2001-10-03 Neopharm, Inc. A method of administering liposomal encapsulated taxane
GB0011927D0 (en) * 2000-05-17 2000-07-05 Inst Biomar Sa New use of citreamicins
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
US20050197405A1 (en) * 2000-11-07 2005-09-08 Li Chiang J. Treatment of hematologic tumors and cancers with beta-lapachone, a broad spectrum anti-cancer agent
AU2002246510B2 (en) 2000-11-09 2007-09-20 Neopharm, Inc. SN-38 lipid complexes and methods of use
US6620843B2 (en) * 2001-01-19 2003-09-16 Pharmagenesis Anticancer treatment using triptolide prodrugs
CA2434270A1 (en) * 2001-01-19 2002-07-25 Bionumerik Pharmaceuticals, Inc. Use of mesna compounds to prevent adverse reactions to anti-neoplastic compositions
US20030149096A1 (en) * 2001-02-05 2003-08-07 Pezzuto John M. Cancer chemopreventative compounds and compositions and methods of treating cancers
IL157357A0 (en) * 2001-03-06 2004-02-19 Bristol Myers Squibb Co A pharmaceutical kit containing tegafur, uracil, folinic acid, paclitaxel and carboplatin
RU2330661C2 (ru) * 2001-03-19 2008-08-10 Новартис Аг Комбинации, включающие антидиарейный агент и эпотилон или производные эпотилона
US6756063B2 (en) * 2001-03-29 2004-06-29 Zoltan Laboratories, Llc Methods and compositions for the treatment of human and animal cancers
US7053072B2 (en) 2001-05-11 2006-05-30 Medimmune Oncology, Inc. Methods for the administration of amifostine and related compounds
US20030045515A1 (en) * 2001-05-24 2003-03-06 Lise Binderup Combination medicament for treatment of neoplastic diseases
WO2003030864A1 (en) * 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
US7186855B2 (en) * 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) * 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6476068B1 (en) 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
US6596320B1 (en) * 2002-01-11 2003-07-22 Bionumerik Pharmaceuticals, Inc. Method for treating cancer having greater efficacy and reduced adverse effects
US6816571B2 (en) * 2002-02-06 2004-11-09 L-3 Communications Security And Detection Systems Corporation Delaware Method and apparatus for transmitting information about a target object between a prescanner and a CT scanner
DK1482973T3 (da) 2002-03-15 2009-12-07 Schering Corp Fremgangsmåde til modulering af CD200-receptorer
US8710095B2 (en) * 2002-04-30 2014-04-29 Bionumerik Pharmaceuticals, Inc. Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity
EP1507759A1 (en) * 2002-05-17 2005-02-23 Leo Pharma A/S Cyanoguanidine produgs
US7253193B2 (en) * 2002-05-17 2007-08-07 Leo Pharma A/S Cyanoguanidine prodrugs
PL228742B1 (pl) * 2002-05-17 2018-05-30 Leo Pharma As Proleki cyjanoguanidynowe, kompozycja farmaceutyczna zawierająca te proleki oraz związki pośrednie
US20040038904A1 (en) * 2002-05-21 2004-02-26 Angela Ogden Method of treating multiple sclerosis
CA2485794C (en) 2002-05-31 2012-10-16 Pharmagenesis, Inc. Triptolide derivatives for modulation of apoptosis and immunosuppression
AU2003261354A1 (en) * 2002-08-02 2004-02-23 The Regents Of The University Of California New uses for inhibitors of inosine monophosphate dehydrogenase
AU2003296897A1 (en) * 2002-08-20 2004-05-04 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
AU2003276689B2 (en) * 2002-09-05 2009-04-09 Bharat Serums And Vaccines Ltd. Liquid stable composition of oxazaphosphorine with mesna
US7025745B2 (en) * 2002-10-07 2006-04-11 Advanced Cardiovascular Systems, Inc. Method of making a catheter balloon using a tapered mandrel
WO2004054569A1 (en) * 2002-12-16 2004-07-01 Council Of Scientific And Industrial Research Pharmaceutical composition containing brevifoliol for use in chemotherapeutic treatment of human beings
US20040203034A1 (en) * 2003-01-03 2004-10-14 The University Of Chicago Optimization of cancer treatment with irinotecan
EA200501252A1 (ru) * 2003-02-03 2006-02-24 Неофарм, Инк. Липосомальная композиция, способ ее получения и лекарственное средство на ее основе (варианты)
WO2004108954A1 (en) * 2003-05-30 2004-12-16 University Of Chicago Methods and compositions for predicting irinotecan toxicity
US20040266808A1 (en) * 2003-06-27 2004-12-30 Kamen Barton A. Treatment of antifolate neurotoxicity
ATE471740T1 (de) * 2003-09-25 2010-07-15 Astellas Pharma Inc Antitumorales mittel mit einem histon-deacetylase-hemmer und einem topoisomerase-ii-hemmer
WO2005062913A2 (en) * 2003-12-24 2005-07-14 Pharmagenesis, Inc. Triplide 5,6-derivatives as immunomodulators and anticancer agents
CN1917893A (zh) * 2004-02-09 2007-02-21 美国泛华医药公司 从雷公藤多苷中分离雷公藤内酯醇化合物的方法
US20050187288A1 (en) * 2004-02-20 2005-08-25 Chiang Li Beta-lapachone and methods of treating cancer
US20050192247A1 (en) * 2004-02-23 2005-09-01 Li Chiang J. Method of treating cancers
JP5057966B2 (ja) * 2004-03-02 2012-10-24 ファーマジェネシス, インコーポレイテッド 免疫調節剤および抗癌剤としてのトリプトライドラクトン環誘導体
US20090247475A1 (en) * 2004-03-05 2009-10-01 The Regents Of The University Of California Methods and compositions relating to pharmacogenetics of different gene variants in the context of irinotecan-based therapies
US7200207B2 (en) * 2004-03-13 2007-04-03 Intrado Inc. Communication network for providing emergency services
US7605137B2 (en) * 2004-03-26 2009-10-20 Vion Pharmaceuticals, Inc. Combination therapy comprising cloretazine
US20090111735A1 (en) * 2004-05-12 2009-04-30 Bionumerik Pharmaceuticals, Inc. Compounds and methods for reducing undesired toxicity of chemotherapeutic agents
US20050256055A1 (en) * 2004-05-12 2005-11-17 Hausheer Frederick H Compounds and methods for reducing undesired toxicity of chemotherapeutic agents
JP4433918B2 (ja) * 2004-07-15 2010-03-17 コニカミノルタエムジー株式会社 画像形成方法
JP4927735B2 (ja) 2004-08-20 2012-05-09 ユニバーシテイ・オブ・バージニア・パテント・フアウンデーシヨン T型カルシウムチャネル阻害剤
US20060063742A1 (en) * 2004-09-21 2006-03-23 Hausheer Frederick H Method of treatment for or protection against lymphedema
TWI366459B (en) * 2004-09-28 2012-06-21 Ind Tech Res Inst Novel hydrophilic analogs of 4,8-dihydrobenzodithiophene-4,8-diones as anticancer agents
US8617906B2 (en) * 2004-10-13 2013-12-31 Pharmagenesis, Inc. Identification and screening of triptolide target molecules
KR100651728B1 (ko) * 2004-11-10 2006-12-06 한국전자통신연구원 정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
EP1838696B1 (en) * 2004-12-22 2016-03-09 Leo Pharma A/S Novel cyanoguanidine compounds
EP1790343A1 (en) * 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
US8026227B2 (en) * 2005-12-13 2011-09-27 Bionumerik Pharmaceuticals, Inc. Chemoprotective methods and compositions
US8143236B2 (en) * 2005-12-13 2012-03-27 Bionumerik Pharmaceuticals, Inc. Chemoprotective methods
US8895531B2 (en) * 2006-03-23 2014-11-25 Rfs Pharma Llc 2′-fluoronucleoside phosphonates as antiviral agents
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
MX2009008487A (es) * 2007-02-09 2010-01-15 Poniard Pharmaceuticals Inc Picoplatino encapsulado.
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
US8372834B2 (en) * 2007-03-02 2013-02-12 University Of Wollongong Compositions and methods for delivery of anti-cancer agents
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
JP2010533714A (ja) * 2007-07-16 2010-10-28 ポニアード ファーマシューティカルズ, インコーポレイテッド ピコプラチンのための経口製剤
CA2701071C (en) * 2007-09-26 2018-03-27 Gemin X Pharmaceuticals Canada Inc. Compositions and methods for effecting nad+ levels using a nicotinamide phosphoribosyl transferase inhibitor
CA2706378C (en) * 2007-11-20 2017-09-12 Lankenau Institute For Medical Research Disulfide chemotherapeutic agents and methods of use thereof
CN101998851A (zh) * 2008-02-08 2011-03-30 帕纳德制药公司 吡铂和西妥昔单抗治疗结直肠癌的用途
CN102014919B (zh) 2008-03-03 2015-02-25 托斯克公司 减少毒性的甲氨蝶呤佐剂及其使用方法
JP2011516412A (ja) * 2008-03-05 2011-05-26 ビカス セラピューティクス,エルエルシー 癌および粘膜炎の治療のための組成物および方法
US9320760B2 (en) * 2008-03-14 2016-04-26 Bionumerik Pharmaceuticals, Inc. Compositions and methods of use of compounds to increase cancer patient survival time
JP5667886B2 (ja) * 2008-03-14 2015-02-12 バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド 癌患者の生存時間を増大させるための組成物及び化合物の使用方法
AU2008352598B2 (en) * 2008-03-14 2012-06-07 Bionumerik Pharmaceuticals, Inc. Chemoprotective methods and compositions
EP2249825B1 (en) * 2008-03-14 2015-10-07 Bionumerik Pharmaceuticals, Inc. Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions
WO2010132771A1 (en) 2009-05-15 2010-11-18 Lankenau Institute For Medical Research Methods and kits for measuring toxicity and oxidative stress in live cells
CA2787673A1 (en) 2010-03-01 2011-09-09 Tau Therapeutics Llc Cancer diagnosis and imaging
EP2590938B1 (en) * 2010-07-09 2017-06-07 Welichem Biotech Inc. Novel sulfonamide compounds for inhibition of metastatic tumor growth
US9271952B2 (en) * 2011-10-11 2016-03-01 Complexa, Inc. Compositions and methods for treating nephropathy
CN102871991B (zh) * 2012-10-24 2014-06-18 中国医学科学院放射医学研究所 二甲双胍在对放化疗损伤起保护作用的药物中的应用
CA2919837A1 (en) * 2013-08-02 2015-02-05 Children's Hospital Medical Center Compositions and methods for treating disease states associated with activated t cells and/or b cells
US9470029B2 (en) 2014-05-30 2016-10-18 Pella Corporation Casement pivot arm roller hinge
CN107810187B (zh) 2015-07-07 2020-09-15 H.隆德贝克有限公司 用于治疗外周疾病的具有咪唑并三嗪酮骨架和咪唑并吡嗪酮骨架的pde9抑制剂
US10537541B2 (en) 2015-10-02 2020-01-21 Complexa Inc. Treatment of focal segmental glomerular sclerosis (FSGS) using therapeutically effective oral doses of 10-nitro-9(E)-octadec-9-enoic acid
CA3100988A1 (en) 2018-05-25 2019-11-28 Imara Inc. Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one
AU2019328299B2 (en) 2018-08-31 2025-02-20 Cardurion Pharmaceuticals, Inc. PDE9 inhibitors for treating sickle cell disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2806866C3 (de) * 1978-02-17 1981-02-12 Asta-Werke Ag Chemische Fabrik, 4800 Bielefeld Verwendung von Salzen von Dithiodialkansulfonsäuren
US4310515A (en) * 1978-05-30 1982-01-12 Bristol-Myers Company Pharmaceutical compositions of cisplatin
US5789000A (en) * 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents

Similar Documents

Publication Publication Date Title
JP2001520189A5 (cg-RX-API-DMAC7.html)
ES2213922T3 (es) Formulaciones y metodos para reducir la toxicidad de agentes antineoplasticos.
JP2003501488A5 (cg-RX-API-DMAC7.html)
HUP9802339A2 (hu) Darifenacint tartalmazó gyógyászati készítmények
EP1061915A4 (en) PHARMACEUTICAL FORMULATIONS OF TAXANES
RU97112888A (ru) Способ, композиции и наборы для повышения пероральной биологической доступности фармацевтических агентов
CN100411628C (zh) 空间位阻的铂配位化合物与非铂抗癌剂的组合及其应用
SI9200403B (en) New combination of a bronchodilator and a steroidal antiinflammatory drug for treatment of respiratory disorders as well as its use and preparation thereof
JP2005525345A5 (cg-RX-API-DMAC7.html)
JP2002524415A5 (cg-RX-API-DMAC7.html)
CA2277365A1 (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
JP2007520452A5 (cg-RX-API-DMAC7.html)
PL363313A1 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
JP2002528502A5 (cg-RX-API-DMAC7.html)
CA2302568A1 (en) Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
JP2007511499A (ja) コンビネーション
AR012731A1 (es) Uso de un derivado de taxano para la preparacion de una composicion farmaceutica , uso de un agente mejorador de la biodicponibilidad de dicho derivado forma de dosificacion oral y conjunto afrmaceutico que lo comprende y metodo para formar a un agente activo biodisponible.
RU2004131214A (ru) Способы лечения когнитивных расстройств
BR0015149A (pt) Método e composições para administração de taxanos oralmente a pacientes humanos
HUT70213A (en) Antiemetic pharmateutilal preparations
JP4610481B2 (ja) 抗腫瘍効果増強剤及び抗腫瘍剤
MXPA03002824A (es) Terapia antitumoral que comprende derivados de distamicina.
AU2002221622A1 (en) Antitumor therapy comprising distamycin derivatives
WO2005013935A3 (en) Composition for releasing a weak base for an extended period of time
JP2009292837A (ja) より効能が大きく副作用の少ない癌治療方法